ALK and non-small cell lung carcinoma: Six ALK-tyrosine kinase inhibitors (TKIs) (crizotinib, ceritinib, alectinib, brigatinib, ensartinib, and lorlatinib) received approval by 2022 for advanced metastatic ALK-rearranged (ALK+) NSCLC treatment.